JP2020524166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524166A5 JP2020524166A5 JP2019570553A JP2019570553A JP2020524166A5 JP 2020524166 A5 JP2020524166 A5 JP 2020524166A5 JP 2019570553 A JP2019570553 A JP 2019570553A JP 2019570553 A JP2019570553 A JP 2019570553A JP 2020524166 A5 JP2020524166 A5 JP 2020524166A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- methyl
- deficiency
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1709824.5 | 2017-06-20 | ||
| GBGB1709824.5A GB201709824D0 (en) | 2017-06-20 | 2017-06-20 | Novel Compounds |
| GB1803561.8 | 2018-03-06 | ||
| GBGB1803561.8A GB201803561D0 (en) | 2018-03-06 | 2018-03-06 | Novel compounds |
| PCT/GB2018/051691 WO2018234775A1 (en) | 2017-06-20 | 2018-06-19 | Substituted cyanopyrrolidines with activity as dub inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524166A JP2020524166A (ja) | 2020-08-13 |
| JP2020524166A5 true JP2020524166A5 (enExample) | 2021-08-05 |
| JP7208931B2 JP7208931B2 (ja) | 2023-01-19 |
Family
ID=62778943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570553A Active JP7208931B2 (ja) | 2017-06-20 | 2018-06-19 | Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11059809B2 (enExample) |
| EP (1) | EP3642196B1 (enExample) |
| JP (1) | JP7208931B2 (enExample) |
| CN (1) | CN110831936B (enExample) |
| WO (1) | WO2018234775A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522267D0 (en) * | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| WO2019071073A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| AU2019356011B2 (en) | 2018-10-05 | 2025-02-06 | Forma Therapeutics, Inc. | Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| WO2023149768A1 (ko) * | 2022-02-07 | 2023-08-10 | 주식회사 내쉬원 | 탈유비퀴틴화효소 억제제를 포함하는 소포체 스트레스 관련 질환 예방 또는 치료용 약학적 조성물 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001077073A1 (en) | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| EP2152079A4 (en) | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| WO2009026197A1 (en) | 2007-08-20 | 2009-02-26 | Glaxo Group Limited | Novel cathepsin c inhibitors and their use |
| CL2009000915A1 (es) | 2008-04-18 | 2010-04-16 | Glaxo Group Ltd | Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd). |
| AR071369A1 (es) | 2008-04-18 | 2010-06-16 | Glaxo Group Ltd | Compuesto de 1- ciano-3-pirrolidinil-n-sustituido-sulfonamida, su uso para preparar un medicamento util para tratar una enfermedad pulmonar obstructiva cronica y composicion farmaceutica que lo comprende |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| PT3049417T (pt) | 2013-07-31 | 2019-01-24 | Merck Patent Gmbh | Piridinas, pirimidinas e pirazinas, como inibidores de btk e utilizações das mesmas |
| WO2015179190A1 (en) | 2014-05-19 | 2015-11-26 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof |
| JP2017516801A (ja) * | 2014-05-27 | 2017-06-22 | ファーマケア，インク． | 脱ユビキチン化酵素阻害剤の組成物と送達の方法 |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| HRP20210791T2 (hr) * | 2015-03-30 | 2021-12-10 | Mission Therapeutics Limited | 1-cijano-pirolidin spojevi kao usp30 inhibitori |
| CN107849013B (zh) | 2015-07-14 | 2022-03-29 | 特殊治疗有限公司 | 作为dub抑制剂用于治疗癌症的氰基吡咯烷类 |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| EP3433246B1 (en) | 2016-03-24 | 2022-05-04 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
-
2018
- 2018-06-19 CN CN201880040925.5A patent/CN110831936B/zh active Active
- 2018-06-19 WO PCT/GB2018/051691 patent/WO2018234775A1/en not_active Ceased
- 2018-06-19 JP JP2019570553A patent/JP7208931B2/ja active Active
- 2018-06-19 EP EP18734921.2A patent/EP3642196B1/en active Active
- 2018-06-19 US US16/615,709 patent/US11059809B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524166A5 (enExample) | ||
| JP2019532938A5 (enExample) | ||
| JP2019533659A5 (enExample) | ||
| JP2019503362A5 (enExample) | ||
| JP2019501142A5 (enExample) | ||
| JP2020521730A5 (enExample) | ||
| JP2019532950A5 (enExample) | ||
| US10000511B2 (en) | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | |
| US20240246915A1 (en) | Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | |
| ES2400070T3 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
| JP7045985B2 (ja) | Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法 | |
| JP2011515337A5 (enExample) | ||
| JP2019532945A5 (enExample) | ||
| JP7328323B2 (ja) | ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物 | |
| JP2019518766A5 (enExample) | ||
| US9649314B2 (en) | Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones | |
| JP2019504009A5 (enExample) | ||
| US20150218148A1 (en) | Benzothiazole Or Benzoxazole Compounds As Sumo Activators | |
| TW202313050A (zh) | 組合療法 | |
| US9896448B2 (en) | Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives | |
| JP5060285B2 (ja) | 固形腫瘍治療剤 | |
| JPWO2006101103A1 (ja) | 造血器腫瘍治療剤 | |
| Sadiq et al. | Amidoximes and their Cyclized Analogue Oxadiazoles as New Frontiers in Chemical Biology: Mini Review | |
| WO2022109311A1 (en) | Methods and materials for increasing nicotinamide phosphoribosyltransferase activity | |
| JPWO2021239863A5 (enExample) |